Back to top
more

Verastem (VSTM)

(Delayed Data from NSDQ)

$9.22 USD

9.22
66,841

-0.10 (-1.02%)

Updated Apr 25, 2024 03:59 PM ET

After-Market: $9.20 -0.02 (-0.16%) 6:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy

by Zacks Equity Research

Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.

All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy

by Zacks Equity Research

Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have boosted sales in the second quarter of 2023 amid severe competition and pricing pressure in the United States.

Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.69% and 33.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.

Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA

by Zacks Equity Research

The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.

Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC

by Zacks Equity Research

Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.

Verastem (VSTM) Enters Overbought Territory

by Zacks Equity Research

Verastem (VSTM) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer

by Zacks Equity Research

Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.

Verastem (VSTM) Jumps: Stock Rises 7.1%

by Zacks Equity Research

Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

Verastem (VSTM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

    Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Is (VSTM) Outperforming Other Medical Stocks This Year?

    Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

    Earnings Estimates Moving Higher for Verastem (VSTM): Time to Buy?

    by Zacks Equity Research

    Verastem (VSTM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

    Has Verastem (VSTM) Outpaced Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (VSTM) Outperforming Other Medical Stocks This Year?

    Verastem Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    Verastem has been struggling lately, but the selling pressure may be coming to an end soon.

    Verastem, Inc. (VSTM) Shares March Higher, Can It Continue?

    by Zacks Equity Research

    As of late, it has definitely been a great time to be an investor in Verastem, Inc. (VSTM).

    Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up

    by Zacks Equity Research

    Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.

    Implied Volatility Surging for Verastem (VSTM) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

    Implied Volatility Surging for Verastem (VSTM) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

    Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Verastem (VSTM) delivered earnings and revenue surprises of 16.67% and -1.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

    Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

    by Zacks Equity Research

    Key highlights of the past week include label expansion of drugs, licensing deals and more.